| pubmed-article:7715734 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7715734 | lifeskim:mentions | umls-concept:C0001814 | lld:lifeskim |
| pubmed-article:7715734 | lifeskim:mentions | umls-concept:C0005456 | lld:lifeskim |
| pubmed-article:7715734 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:7715734 | lifeskim:mentions | umls-concept:C1515877 | lld:lifeskim |
| pubmed-article:7715734 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:7715734 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7715734 | pubmed:dateCreated | 1995-5-12 | lld:pubmed |
| pubmed-article:7715734 | pubmed:abstractText | It has been suggested that agmatine (decarboxylated arginine) is an endogenous clonidine-displacing substance (CDS) which recognizes alpha 2-adrenoceptor and non-adrenoceptor, imidazoline binding sites. We have examined the effect of agmatine at alpha 2-adrenoceptor binding sites and pre- and postjunctional alpha 2-adrenoceptors. Agmatine produced a concentration-dependent inhibition of 1 nmol/l 3H-clonidine binding to both rat (pKi-5.10 +/- 0.05) and bovine (pKi-4.77 +/- 0.38) cerebral cortex membranes. However, agmatine (0.1-100 microM) failed to activate pre-junctional alpha 2-adrenoceptors regulating transmitter release in the guinea-pig isolated ileum and rat isolated vas deferens, nor did it activate postjunctional alpha 2-adrenoceptors of the porcine isolated palmar lateral vein which mediate contraction or inhibition of forskolin-stimulated cyclic AMP formation. High concentrations of agmatine (10-30-fold the pKi at alpha 2-adrenoceptor binding sites) failed to influence alpha 2-adrenoceptor activation by either clonidine or UK-14304 (5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline bitartrate) in any of the peripheral preparations examined. Moreover, even in a preparation where an interaction with alpha 2-adrenoceptor binding sites on cell membranes can be demonstrated, the rat cerebral cortex, agmatine failed to inhibit forskolin-stimulated cyclic AMP in the intact tissue or affect the inhibition produced by the selective alpha 2-adrenoceptor agonist UK-14304. Agmatine was also devoid of agonist activity in two preparations, the rat isolated thoracic aorta and the rat isolated gastric fundus, in which CDS has been reported to produce non-adrenoceptor effects. Thus, we have confirmed that agmatine recognizes alpha 2-adrenoceptor binding sites and, therefore, is a CDS.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7715734 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7715734 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7715734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7715734 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7715734 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7715734 | pubmed:issn | 0028-1298 | lld:pubmed |
| pubmed-article:7715734 | pubmed:author | pubmed-author:MasonRR | lld:pubmed |
| pubmed-article:7715734 | pubmed:author | pubmed-author:KendallD ADA | lld:pubmed |
| pubmed-article:7715734 | pubmed:author | pubmed-author:WrightI KIK | lld:pubmed |
| pubmed-article:7715734 | pubmed:author | pubmed-author:WilsonV GVG | lld:pubmed |
| pubmed-article:7715734 | pubmed:author | pubmed-author:MillonJJ | lld:pubmed |
| pubmed-article:7715734 | pubmed:author | pubmed-author:PinthongDD | lld:pubmed |
| pubmed-article:7715734 | pubmed:author | pubmed-author:HanmerCC | lld:pubmed |
| pubmed-article:7715734 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7715734 | pubmed:volume | 351 | lld:pubmed |
| pubmed-article:7715734 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7715734 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7715734 | pubmed:pagination | 10-6 | lld:pubmed |
| pubmed-article:7715734 | pubmed:dateRevised | 2010-8-25 | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:meshHeading | pubmed-meshheading:7715734-... | lld:pubmed |
| pubmed-article:7715734 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7715734 | pubmed:articleTitle | Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors. | lld:pubmed |
| pubmed-article:7715734 | pubmed:affiliation | Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham, UK. | lld:pubmed |
| pubmed-article:7715734 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7715734 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:7715734 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7715734 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7715734 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7715734 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7715734 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7715734 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7715734 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7715734 | lld:pubmed |
